Clinical trial NCT04597827: Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease
Official title: Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Semantic Dementia
Alzheimer Disease
Healthy
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Alzheimer's disease will be patients at the CHU of Grenoble.

Patients with Alzheimer's disease will be recruited in the CHU Grenoble, CHU Angers, CHU Bordeaux, CHU Colmar, CHU Lyon, CHU Rennes and CHUV Lausanne.

Controls will be recruited via the database "Seniors pour la Science ", https://seniorspourlascience.fr/

Brief summary: This study aims at exploring patients' ability to monitor their own memory performance depending on their primary deficit and the type of memory involved in the criterion task. The goal is to evaluate if semantic dementia (SD) and Alzheimer's disease (AD) differently affect patients' awareness of their memory abilities.

Detailed description: Patients who will give their informed non-opposition will be included. Participants will undergo 6 metacognitive tasks in which they will be tested on newly learnt information (i.e., episodic memory) or prior knowledge (i.e., semantic memory) and asked to evaluate their performance either prior or after the test. Correlation between their evaluation and their actual performance will be measured. Performance and correlations will be compared across groups.

Eligibility criteria: Inclusion Criteria:

* native French-speakers
* normal or corrected-to-normal vision
* for patients ONLY : doctor-approved diagnosis of semantic dementia or Alzheimer's disease
* for healthy participants ONLY: score above 27 on the MMSE
* non-opposition in participation

Exclusion Criteria:

* other neurological/ psychiatric disorder, or cognitive disorder that might affect general cognition
* drug or alcohol abuse

Primary outcomes:
measure: Metacognitive bias on the episodic predictive judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive accuracy on the episodic predictive judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive bias on the semantic predictive judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive accuracy on the semantic predictive judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive bias on episodic global judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive bias on semantic global judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive bias on the episodic retrospective judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive accuracy on the episodic retrospective judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive bias on the semantic retrospective judgment task
timeFrame: End of study : around May 2022
measure: Metacognitive accuracy on the semantic retrospective judgment task
timeFrame: End of study : around May 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU Angers
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Bron
country: France
facility: Hôpital Neurologique de Lyon
city: Colmar
country: France
facility: Hôpitaux Civils Colmar
city: Grenoble
country: France
facility: Chu Grenoble Alpes
city: Rennes
country: France
facility: CHU Rennes
city: Lausanne
country: Switzerland
facility: CHU Vaudois
Study officials:
affiliation: University Hospital, Grenoble
name: Olivier MOREAUD
role: PRINCIPAL_INVESTIGATOR
References: